Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target

Malarial dihydrofolate reductase (DHFR) is the target of antifolate antimalarial drugs such as pyrimethamine and cycloguanil, the clinical efficacy of which have been compromised by resistance arising through mutations at various sites on the enzyme. Here, we describe the use of cocrystal structures...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Yuthavong, Yongyuth, Tarnchompoo, Bongkoch, Vilaivan, Tirayut, Chitnumsub, Penchit, Kamchonwongpaisan, Sumalee, Charman, Susan A., McLennan, Danielle N., White, Karen L., Vivas, Livia, Bongard, Emily, Thongphanchang, Chawanee, Taweechai, Supannee, Vanichtanankul, Jarunee, Rattanajak, Roonglawan, Arwon, Uthai, Fantauzzi, Pascal, Yuvaniyama, Jirundon, Charman, William N., Matthews, David
Format: Artigo
Idioma:Inglês
Publicat: National Academy of Sciences 2012
Matèries:
Biological Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3479511/
https://ncbi.nlm.nih.gov/pubmed/23035243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1204556109
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars